Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
Myriad Genetics (NASDAQ: MYGN) will present its transformation and growth initiatives at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) will present its transformation and growth initiatives at the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 11, 2021, at 2:50 p.m. EST. CEO Paul J. Diaz will focus on how the company is leveraging precision medicine to enhance patient care and lower healthcare costs. The event will be accessible via a live audio webcast on Myriad's website, aiming to shed light on key opportunities to improve diagnostics and treatment strategies.
Details
News Market Reaction – MYGN
The recorded move for MYGN in the trading session of this news was +0.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the company’s transformation and growth initiatives at the 39th Annual J.P. Morgan Healthcare Conference at 2:50 p.m. EST on January 11, 2021.
Mr. Diaz will focus on key opportunities to fulfill the company’s mission of improving patient lives by unlocking the power of precision medicine and helping healthcare providers and payers prevent, diagnose and treat disease through the company’s genetic insights. The presentation will be available via a live audio webcast accessible at the following direct link or through the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading precision medicine company dedicated improving and transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across in specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. For more information, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
| Media Contact: | Investor Contact: |
| Jared Maxwell | Scott Gleason |
| (801) 505-5027 | (801) 584-1143 |
| jmaxwell@myriad.com | sgleason@myriad.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.